Innovations in the Clinical Research of Chronic Myeloid Leukemia: From Targeted Therapies to Allogeneic Stem Cell Transplantation
A special issue of Current Oncology (ISSN 1718-7729). This special issue belongs to the section "Hematology".
Deadline for manuscript submissions: 28 February 2026 | Viewed by 42
Special Issue Editor
Special Issue Information
Dear Colleagues,
Chronic myeloid leukemia (CML) has undergone remarkable therapeutic advancements in recent decades, transforming it from a fatal disease to a manageable chronic condition for most patients. The introduction of tyrosine kinase inhibitors (TKIs) revolutionized CML treatment, yet challenges remain in managing resistance, treatment discontinuation, and disease progression. Allogeneic stem cell transplantation continues to play a crucial role for eligible patients, particularly those with advanced disease or TKI failure.
This Special Issue aims to highlight the latest innovations in CML clinical research, spanning from novel targeted therapies to optimized transplantation approaches. We welcome contributions that explore emerging treatment strategies, mechanisms of resistance, biomarkers for treatment response, and advancements in transplantation techniques. Original research and reviews addressing minimal residual disease monitoring, treatment-free remission strategies, and personalized treatment approaches are particularly encouraged.
This Special Issue will provide a comprehensive overview of current challenges and future directions in CML management, with the goal of improving outcomes for all patient populations.
Dr. Jeffrey H. Lipton
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Current Oncology is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- chronic myeloid leukemia
- tyrosine kinase inhibitors
- treatment resistance
- allogeneic stem cell transplantation
- stem cell persistence
- treatment-free remission
- targeted therapies
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
